APA

Almadiyeva A., Ibrayev S., Turgambayeva A., Kostyuk A., Khismetova Z. & Akhmetova Z. (2018). Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. : Iranian journal of public health.

Chicago

Almadiyeva Alima, Ibrayev Serik, Turgambayeva Assiya, Kostyuk Alexandr, Khismetova Zayituna and Akhmetova Zhanar. 2018. Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. : Iranian journal of public health.

Harvard

Almadiyeva A., Ibrayev S., Turgambayeva A., Kostyuk A., Khismetova Z. and Akhmetova Z. (2018). Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. : Iranian journal of public health.

MLA

Almadiyeva Alima, Ibrayev Serik, Turgambayeva Assiya, Kostyuk Alexandr, Khismetova Zayituna and Akhmetova Zhanar. Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. : Iranian journal of public health. 2018.